mounjaro tirzepatide patent expiry These highlights do not include all the information needed to use safely and effectively. See full prescribing information for MOUNJARO. MOUNJARO® (tirzepatide) Injection, for subcutaneous use Initial U.S. Approval: 2022 Looming GLP-1 drug patent expirations

Patients on tirzepatide also tend to experience fewer and milder side effects than patients on semaglutide

WahlstrmASayinSIMarschallH-UBckhedF

Yes: most users report energy returning to baseline or improving above baseline by weeks 812 as appetite suppression stabilizes and eating patterns become predictable

It isnt contagious or dangerous, and there is no permanent cure but a range of treatments (phototherapy, topical creams including JAK-inhibitors, and grafting for stable cases) can help repigment skin and slow spread

doi:10.1007/s00204-010-0544-6

Other typical reactions can include redness, mild bruising or discomfort at injection sites, which usually subside within 48 hours